{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:05:27Z","timestamp":1791889527600,"version":"4.3.4"},"reference-count":60,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T00:00:00Z","timestamp":1519689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.ekir.2018.02.010","type":"journal-article","created":{"date-parts":[[2018,3,3]],"date-time":"2018-03-03T17:12:17Z","timestamp":1520097137000},"page":"784-793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome"],"prefix":"10.1016","volume":"3","author":[{"given":"Donal J.","family":"Sexton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan G.","family":"de Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colm","family":"Magee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Conlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conall M.","family":"O\u2019Seaghdha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2018.02.010_bib1","unstructured":"University of North Carolina School of Medicine Kidney Center. UNC Kidney Center. Available at: https:\/\/unckidneycenter.org\/."},{"key":"10.1016\/j.ekir.2018.02.010_bib2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2215\/CJN.10131011","article-title":"Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease","volume":"7","author":"Kerlin","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2018.02.010_bib3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1055\/s-0033-1343887","article-title":"Thrombosis in nephrotic syndrome","volume":"39","author":"Barbano","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.ekir.2018.02.010_bib4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.thromres.2005.03.030","article-title":"Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management","volume":"118","author":"Singhal","year":"2006","journal-title":"Thromb Res"},{"key":"10.1016\/j.ekir.2018.02.010_bib5","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.ekir.2017.04.004","article-title":"Ischemic stroke of possible embolic etiology associated with nephrotic syndrome","volume":"2","author":"Roy","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2018.02.010_bib6","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1159\/000345475","article-title":"Serum D-dimer concentrations in nephrotic syndrome track with albuminuria, not estimated glomerular filtration rate","volume":"36","author":"Sexton","year":"2012","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2018.02.010_bib7","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199804233381707","article-title":"The nephrotic syndrome","volume":"338","author":"Orth","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2018.02.010_bib8","doi-asserted-by":"crossref","first-page":"916760","DOI":"10.1155\/2014\/916760","article-title":"Primary nephrotic syndrome in adults as a risk factor for pulmonary embolism: an up-to-date review of the literature","volume":"2014","author":"Mirrakhimov","year":"2014","journal-title":"Int J Nephrol"},{"key":"10.1016\/j.ekir.2018.02.010_bib9","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000183667","article-title":"Concentration of three thrombin inhibitors in the nephrotic syndrome in adults","volume":"42","author":"Rydzewski","year":"1986","journal-title":"Nephron"},{"key":"10.1016\/j.ekir.2018.02.010_bib10","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1136\/bmj.2.6048.1361","article-title":"Factor VII deficiency associated with nephrotic syndrome","volume":"2","author":"Epstein","year":"1976","journal-title":"Br Med J"},{"key":"10.1016\/j.ekir.2018.02.010_bib11","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1681\/ASN.2006111300","article-title":"Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum","volume":"18","author":"Glassock","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2018.02.010_bib12","first-page":"739","article-title":"Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT-III: a pilot study","volume":"15","author":"Zhang","year":"2018","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.ekir.2018.02.010_bib13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000362162","article-title":"Carotid thromboembolism associated with nephrotic syndrome treated with dabigatran","volume":"4","author":"Sasaki","year":"2014","journal-title":"Case Rep Nephrol Urol"},{"key":"10.1016\/j.ekir.2018.02.010_bib14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ancard.2014.08.010","article-title":"[Nephrotic syndrome revealed by pulmonary embolism: about four cases]","volume":"63","author":"Chaudesaygues","year":"2014","journal-title":"Ann Cardiol Angeiol [Paris]"},{"key":"10.1016\/j.ekir.2018.02.010_bib15","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.2169\/internalmedicine.8742-16","article-title":"Edoxaban was effective for treating renal vein thrombosis in a patient with nephrotic syndrome","volume":"56","author":"Shimada","year":"2017","journal-title":"Intern Med"},{"key":"10.1016\/j.ekir.2018.02.010_bib16","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1177\/1060028014549349","article-title":"Use of rivaroxaban in a patient with history of nephrotic syndrome and hypercoagulability","volume":"48","author":"Dupree","year":"2014","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ekir.2018.02.010_bib17","doi-asserted-by":"crossref","first-page":"983A","DOI":"10.1378\/chest.2280343","article-title":"Failure of anticoagulation in a case of nephrotic syndrome with recurrent thromboembolism","volume":"148","author":"Basu","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.ekir.2018.02.010_bib18","article-title":"Venous and arterial thromboses in nephrotic syndrome: where only warfarin has walked","volume":"31","author":"Kamran","year":"2016","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.ekir.2018.02.010_bib19","first-page":"64","article-title":"Warfarin vs new oral anticoagulant in primary adult nephrotic syndrome associated venous thormboembolism","volume":"22","author":"Han","year":"2017","journal-title":"Nephrology"},{"key":"10.1016\/j.ekir.2018.02.010_bib20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000448628","article-title":"Venous thromboembolism in primary nephrotic syndrome\u2014is the risk high enough to justify prophylactic anticoagulation?","volume":"135","author":"Rankin","year":"2017","journal-title":"Nephron"},{"key":"10.1016\/j.ekir.2018.02.010_bib21","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/ki.2011.312","article-title":"Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis","volume":"81","author":"Barbour","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2018.02.010_bib22","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00467-013-2525-5","article-title":"Venous thromboembolism in pediatric nephrotic syndrome","volume":"29","author":"Kerlin","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2018.02.010_bib23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.107.716951","article-title":"High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study","volume":"117","author":"Mahmoodi","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2018.02.010_bib24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/ndt\/gfw227","article-title":"Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome","volume":"32","author":"Gyamlani","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2018.02.010_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2215\/CJN.04250511","article-title":"Venous thromboembolism in patients with membranous nephropathy","volume":"7","author":"Lionaki","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2018.02.010_bib26","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2215\/CJN.07190713","article-title":"Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome","volume":"9","author":"Medjeral-Thomas","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2018.02.010_bib27","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1345\/aph.1R530","article-title":"Prophylaxis of thromboembolic events in patients with nephrotic syndrome","volume":"47","author":"Pincus","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ekir.2018.02.010_bib28","first-page":"139","article-title":"KDIGO clinical practice guideline for glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int. Suppl"},{"key":"10.1016\/j.ekir.2018.02.010_bib29","doi-asserted-by":"crossref","first-page":"950.e915","DOI":"10.1016\/j.cjca.2017.03.020","article-title":"Acute myocardial infarction in a young girl with nephrotic syndrome: a case report and literature review","volume":"33","author":"Zhao","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ekir.2018.02.010_bib30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/20009666.2017.1286814","article-title":"Popliteal arterial thrombosis in nephrotic syndrome: a case report","volume":"7","author":"Tachamo","year":"2017","journal-title":"J\u00a0Community Hosp Intern Med Perspect"},{"key":"10.1016\/j.ekir.2018.02.010_bib31","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2018.02.010_bib32","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.kint.2016.01.019","article-title":"Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy?","volume":"89","author":"Hofstra","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2018.02.010_bib33","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ajh.21603","article-title":"Systemic AL amyloidosis with acquired factor X deficiency: a study of perioperative bleeding risk and treatment outcomes in 60 patients","volume":"85","author":"Thompson","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ekir.2018.02.010_bib34","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2018.02.010_bib35","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1681\/ASN.2016090980","article-title":"Apixaban pharmacokinetics at steady state in hemodialysis patients","volume":"28","author":"Mavrakanas","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2018.02.010_bib36","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1161\/CIRCULATIONAHA.112.113944","article-title":"Association of mild to moderate chronic kidney disease with venous thromboembolism: pooled analysis of five prospective general population cohorts","volume":"126","author":"Mahmoodi","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2018.02.010_bib37","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/ndt\/gfq443","article-title":"Estimated glomerular filtration rate in the nephrotic syndrome","volume":"26","author":"Hofstra","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2018.02.010_bib38","first-page":"540","article-title":"Serum phosphate varies with degree of proteinuria in nephrotic syndrome and is associated with elevated pulse wave velocity","volume":"26","author":"Sexton","year":"2013","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.ekir.2018.02.010_bib39","first-page":"CD011373","article-title":"Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease","volume":"11","author":"Kimachi","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ekir.2018.02.010_bib40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/MNH.0000000000000098","article-title":"Comparison of novel oral anticoagulants versus vitamin K antagonists in patients with chronic kidney disease","volume":"24","author":"Harel","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.ekir.2018.02.010_bib41","unstructured":"National Institute of Health. National Library of Medicine. Available at: https:\/\/clinicaltrials.gov\/."},{"key":"10.1016\/j.ekir.2018.02.010_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ekir.2018.02.010_bib43","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bcp.12075","article-title":"Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects","volume":"76","author":"Mueck","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ekir.2018.02.010_bib44","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","article-title":"Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"70","author":"Kubitza","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ekir.2018.02.010_bib45","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/0976-500X.124409","article-title":"The new Factor Xa inhibitor: apixaban","volume":"5","author":"Bhanwra","year":"2014","journal-title":"J\u00a0Pharmacol Pharmacother"},{"key":"10.1016\/j.ekir.2018.02.010_bib46","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective Factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial","volume":"119","author":"Alexander","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2018.02.010_bib47","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1110899","article-title":"Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients","volume":"365","author":"Goldhaber","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2018.02.010_bib48","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1681\/ASN.2017030361","article-title":"Indoxyl sulfate upregulates liver p-glycoprotein expression and activity through aryl hydrocarbon receptor signaling","volume":"29","author":"Santana Machado","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2018.02.010_bib49","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/1753944717714921","article-title":"Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment","volume":"11","author":"Turpie","year":"2017","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.ekir.2018.02.010_bib50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12959-017-0137-1","article-title":"Perioperative management of patients on direct oral anticoagulants","volume":"15","author":"Dubois","year":"2017","journal-title":"Thromb J"},{"key":"10.1016\/j.ekir.2018.02.010_bib51","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1681\/ASN.2016070789","article-title":"Thrombin-induced podocyte injury is protease-activated receptor dependent","volume":"28","author":"Sharma","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2018.02.010_bib52","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/ki.1988.129","article-title":"Extrarenal complications of the nephrotic syndrome","volume":"33","author":"Bernard","year":"1988","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2018.02.010_bib53","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/FTD.0000000000000356","article-title":"Effect of the direct oral anticoagulants rivaroxaban and apixaban on the disposition of calcineurin inhibitors in transplant recipients","volume":"39","author":"Vanhove","year":"2017","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ekir.2018.02.010_bib54","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jama.2017.13883","article-title":"Association between use of\u00a0non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation","volume":"318","author":"Chang","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2018.02.010_bib55","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/VHRM.S138890","article-title":"Reversal of direct oral anticoagulants","volume":"13","author":"Almegren","year":"2017","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.ekir.2018.02.010_bib56","first-page":"141","article-title":"Reversing factor Xa inhibitors\u2014clinical utility of andexanet\u00a0alfa","volume":"8","author":"Kaatz","year":"2017","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.ekir.2018.02.010_bib57","unstructured":"National Institute of Health, U.S. National Library of Medicine. Available at: https:\/\/clinicaltrials.gov\/ct2\/results?cond=andexanet+alfa&term=&cntry1=&state1=&recrs=."},{"key":"10.1016\/j.ekir.2018.02.010_bib58","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1016\/j.jacc.2017.09.1085","article-title":"2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways","volume":"70","author":"Tomaselli","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ekir.2018.02.010_bib59","unstructured":"NEPTUNE. Nephrotic Syndrome Study Network. Available at: https:\/\/www.rarediseasesnetwork.org\/cms\/NEPTUNE."},{"key":"10.1016\/j.ekir.2018.02.010_bib60","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.autrev.2014.01.053","article-title":"14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends","volume":"13","author":"Erkan","year":"2014","journal-title":"Autoimmun Rev"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246802491830041X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246802491830041X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T18:46:08Z","timestamp":1719859568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246802491830041X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S246802491830041X"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2018.02.010","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2018.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}